Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Almirall

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Almirall's 2013 sales performance.

Pharma deals during July 2014

Pharma deals during July 2014 AZ will also acquire Almirall Sofotec, Almirall's inhalation device business which includes Genuair, its novel multi-dose dry powder inhalation (DPI) device. ... Almirall will receive $875m upfront and up to $1.22bn in development, launch, and

FDA approves Boehringer COPD spray Striverdi Respimat

FDA approves Boehringer COPD spray Striverdi Respimat Meanwhile Almirall, whose respiratory franchise is to be bought by AstraZeneca in a $2bn deal, has its own COPD combination - aclidinium bromide/formoterol candidate - in phase III with Forest Labs.

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio

AstraZeneca signs $2bn deal to buy Almirall respiratory portfolio Commenting on the Almirall deal Soriot said: “We will benefit from immediate and growing product revenues which we anticipate will be rapidly accretive to earnings. ... Almirall president Jorge Gallardo said the AZ deal would “better develop our

GSK trial throws everything at COPD

GSK trial throws everything at COPD Meanwhile, and Forest Labs/Almirall are all bringing their own LAMA/LABA combinations through the pipeline, so GSK's triple therapy approach could help it stay ahead of the pack.

GSK's Anoro backed in Europe for COPD

GSK's Anoro backed in Europe for COPD and Forest Labs/Almirall are also bringing their own LAMA/LABA combinations through development.

[ Previous 5 results ] 6 7 8 9 10 11 12 13 14 15 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...